– Signant acquires DSG to enhance its suite of eClinical solutions for traditional and decentralized clinical trials
PHILADELPHIA, July 17, 2023 /PRNewswire/ — Signant Health, a leader in test generation for modern clinical trials, today announced the acquisition of DSG, a leading provider of electronic data capture (EDC) and direct data capture technology. data (DDC) within a unified eClinical suite, for decentralized and center-based clinical trials.
By adding the capabilities of DSG solutions, Signant now offers more choice to clients and further differentiates itself as a leader in comprehensive digitization solutions for clinical trials of all sizes and types, each fully supported by science, scale and operating experience.
Signant’s management team selected DSG based on a comprehensive study of its suite of solutions, recognizing the opportunities inherent in its key features, including: (1) ease of use – where individual centers provided positive feedback; (2) operational efficiency – combines fast study startup times with superior workflow tools and source data remote verification (SDV) capabilities; (3) flexibility – easily adapts to the requirements of the simplest as well as the most complex study designs; and (4) customer satisfaction – backed by a proactive and attentive service package.
DSG’s 20+ years of experience and proven success serving biotechs, large pharmaceutical organizations, and contract research organizations (CROs) is a perfect fit with Signant’s organizational strategy and goals.
“We believe that DSG is the industry’s best kept secret. We are delighted to welcome the DSG team to Signant, allowing us to expand our product suite to include comprehensive EDC/DDC capabilities,” said Roger Smith, Counsel Signant delegate. “Signant and DSG are passionate about supporting the trial ecosystem with software, analytics, and logistics solutions to conduct studies and generate data across modalities, while simplifying and supporting the role of investigators, sponsors, and CROs.” He added: “DSG’s unified platform, including a fully featured EDC/DDC solution, is an important component in our strategy to deliver comprehensive end-to-end capabilities to truly digitize clinical trials, and deliver user-friendly solutions.” to support all levels of trial decentralization.”
“With this acquisition, we are able to support our clients and their sites better than ever by leveraging Signant’s deep operational, regulatory and scientific expertise, as well as its global scale and reach,” said Elias Tharakan, DSG’s CTO. “As a Signant Health company, DSG could not be more excited and optimistic about the future of clinical research and the ability for sponsors and sites to take advantage of optimized technology solutions to meet the needs of modern clinical trials.”
For more information, visit https://www.signanthealth.com/best-edc.
About Signant Health
Signant Health is the test generation company. We focus on leveraging software, deep therapeutic and scientific knowledge, and operational experience to consistently capture, aggregate, and reveal quality evidence for clinical studies across traditional, virtual, and hybrid trial models. For more than 25 years, more than 600 sponsors and CROs of all sizes – including all of the Top 20 pharmas – have trusted Signant solutions for remote and site-based eCOA, EDC, eConsent, RTSM, chain management supply and analysis of data quality. More information on the website www.signanthealth.com.
Logo – https://mma.prnewswire.com/media/1202052…
Contacto: Heather Bilinski media@signanthealth.com 1 (610) 400-4141
View original content to download multimedia: https://www.prnewswire.com/news-releases/signant-adquiere-dsg-para-mejorar-su-paquete-de-soluciones-eclinical-301868011.html
